Pirbuterol free base | CAS#38677-81-5 | 38029-10-6 | β2 adrenoreceptor agonist

MedKoo Cat#: 526004 | Name: Pirbuterol

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pirbuterol is a short-acting β2 adrenoreceptor agonist with bronchodilating action used in the treatment of asthma.

Chemical Structure

Pirbuterol

CAS#38677-81-5 (free base)

Theoretical Analysis

MedKoo Cat#: 526004

Name: Pirbuterol

CAS#: 38677-81-5 (free base)

Chemical Formula: C12H20N2O3

Exact Mass: 240.1474

Molecular Weight: 240.30

Elemental Analysis: C, 59.98; H, 8.39; N, 11.66; O, 19.97

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

38029-10-6 (HCl) 38677-81-5 (free base) 65652-44-0 (acetate)

Synonym

Pirbuterol; Pirbuterolum; Pirbuterolum [INN-Latin]; CP-24,314-14.

IUPAC/Chemical Name

Ethanol, 2-tert-butylamino-1-(5-hydroxy-6-hydroxymethyl-2-pyridyl)-

InChi Key

VQDBNKDJNJQRDG-UHFFFAOYSA-N

InChi Code

InChI=1S/C12H20N2O3/c1-12(2,3)13-6-11(17)8-4-5-10(16)9(7-15)14-8/h4-5,11,13,15-17H,6-7H2,1-3H3

SMILES Code

OCC1=C(O)C=CC(C(O)CNC(C)(C)C)=N1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 240.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Bonniaud P, Favrolt N, Collet E, Dumas JP, Guilloux L, Pauli G, Camus P. Salbutamol, terbutaline and pirbuterol allergy in an asthmatic patient. Allergy. 2007 Oct;62(10):1219-20. PubMed PMID: 17845596. 2: Derksen FJ, Olszewski M, Robinson NE, Berney C, Lloyd JW, Hakala J, Matson C, Ruth D. Use of a hand-held, metered-dose aerosol delivery device to administer pirbuterol acetate to horses with 'heaves'. Equine Vet J. 1996 Jul;28(4):306-10. PubMed PMID: 8818596. 3: Ashutosh K, Dev G, Steele D. Nonbronchodilator effects of pirbuterol and ipratropium in chronic obstructive pulmonary disease. Chest. 1995 Jan;107(1):173-8. PubMed PMID: 7813271. 4: Tinkelman DG, Vanden Burgt JA, Ekholm BP. Double-blind, clinical efficacy study comparing 400 micrograms of pirbuterol versus placebo delivered by a breath-actuated aerosol inhaler. J Asthma. 1994;31(3):187-92. PubMed PMID: 7910819. 5: Solé D, Villalba SR, Sestelo MR, Scalabrin DM, Soares FJ, Naspitz CK. Maximum bronchodilator effect of pirbuterol and procaterol administered as sprays with and without an aerochamber. Rev Paul Med. 1993 May-Jun;111(3):397-402. PubMed PMID: 8108632. 6: Bronsky EA, Debelic M, Pujet JC, Hahn M. Ease-of-use study of pirbuterol acetate in the Autohaler actuator in three countries: the United States, Germany, and France. J Asthma. 1993;30(6):439-43. PubMed PMID: 8244913. 7: Derksen FJ, Robinson NE, Berney CE. Aerosol pirbuterol: bronchodilator activity and side effects in ponies with recurrent airway obstruction (heaves). Equine Vet J. 1992 Mar;24(2):107-12. PubMed PMID: 1582387. 8: Dry J, Pradalier A, Michel FB, Pariente R, Boutin C. [Pirbuterol: a new beta 2-sympathomimetic agent. An open multicenter study]. Therapie. 1991 May-Jun;46(3):253-4. French. PubMed PMID: 1792660. 9: Völkl KP, Kroll VM, Wiesemann HG, Schneider B. Clinical efficacy of two beta 2-sympathicomimetics in different inhalers in children with asthma. Comparison of pirbuterol in a breath-actuated inhaler and salbutamol in a customary metered-dose inhaler. Arzneimittelforschung. 1991 May;41(5):533-6. PubMed PMID: 1680327. 10: Bonomi L, Perfetti S, Bellucci R, De Franco I. Ocular hypotensive activity of pirbuterol eye drops in rabbits. J Ocul Pharmacol. 1991 Fall;7(3):191-4. PubMed PMID: 1686050. 11: Windom H, Grainger J, Burgess C, Crane J, Pearce N, Beasley R. A comparison of the haemodynamic and hypokalaemic effects of inhaled pirbuterol and salbutamol. N Z Med J. 1990 Jun 13;103(891):259-61. PubMed PMID: 1972557. 12: Hoffarth HP, Freyberger H, Völkl KP, Ulmer WT. [Inhalation therapy with selective beta 2-sympathomimetic drugs. Effect of pirbuterol administered via the Autohaler and salbutamol administered via the Diskhaler in obstructive respiratory tract disease]. Fortschr Med. 1990 Mar 20;108(8):162-4. German. PubMed PMID: 2186991. 13: Tinkelman DG, Brandon ML, Grieco M, Hudson L, Rosenthal RR, Spector SL, Tashkin D, Votteri B. Comparison of safety and efficacy of inhaled pirbuterol with metaproterenol. Ann Allergy. 1990 Feb;64(2 Pt 2):202-6. PubMed PMID: 2405746. 14: Biernacki W, Prince K, Whyte K, MacNee W, Flenley DC. The effect of six months of daily treatment with the beta-2 agonist oral pirbuterol on pulmonary hemodynamics in patients with chronic hypoxic cor pulmonale receiving long-term oxygen therapy. Am Rev Respir Dis. 1989 Feb;139(2):492-7. PubMed PMID: 2563321. 15: Neilly JB, Carter R, Tweddel A, Martin W, Hutton I, Banham SW, Stevenson RD. Long term haemodynamic, pulmonary function and symptomatic effects of pirbuterol in COPD. Respir Med. 1989 Jan;83(1):59-65. PubMed PMID: 2511610. 16: Chodosh S, Crooks LA, Tuck J. Comparative effects of pirbuterol acetate, metaproterenol, and placebo aerosols on pulmonary function and incidence of cardiac ectopy. J Asthma. 1989;26(5):309-15. PubMed PMID: 2484663. 17: Canepa-Anson R, Dawson JR, Kuan P, Poole-Wilson PA, Sutton GC, Cockrill B, Reuben SR. Differences between acute and long-term metabolic and endocrine effects of oral beta-adrenoceptor agonist therapy with pirbuterol for cardiac failure. Br J Clin Pharmacol. 1987 Feb;23(2):173-81. PubMed PMID: 3828194; PubMed Central PMCID: PMC1386065. 18: Nurnberger JI Jr, Kessler L, Simmons-Alling S, Gershon ES. Pirbuterol trial as antidepressant. Biol Psychiatry. 1986 May;21(5-6):565-6. PubMed PMID: 2870743. 19: Uretsky BF, Seecof RM, Reddy PS. The acute hemodynamic response to pirbuterol at rest and exercise in patients with heart failure with observations on long-term response. Can J Cardiol. 1986 Mar-Apr;2(2):80-5. PubMed PMID: 3085906. 20: Mohamed ME, Aboul-Enein HY. Fluorometric and spectrophotometric determination of pirbuterol hydrochloride in authentic and dosage forms. J Assoc Off Anal Chem. 1985 Nov-Dec;68(6):1222-5. PubMed PMID: 4086446.